| Identification | Back Directory | [Name]
DMH2 | [CAS]
1206711-14-9 | [Synonyms]
DMH2
VU 0364849
DMH2 >=98% (HPLC)
4-[6-[4-[2-(4-Morpholinyl)ethoxy]phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | [Molecular Formula]
C27H25N5O2 | [MDL Number]
MFCD29917837 | [MOL File]
1206711-14-9.mol | [Molecular Weight]
451.52 |
| Chemical Properties | Back Directory | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
powder | [pka]
6.27±0.10(Predicted) | [color ]
white to beige | [InChI]
1S/C27H25N5O2/c1-2-4-26-24(3-1)23(9-10-28-26)25-18-30-32-19-21(17-29-27(25)32)20-5-7-22(8-6-20)34-16-13-31-11-14-33-15-12-31/h1-10,17-19H,11-16H2 | [InChIKey]
DXLXRNZCYAYUED-UHFFFAOYSA-N | [SMILES]
N1(CCOC2=CC=C(C(C=N3)=CN4C3=C(C5=CC=NC6=C5C=CC=C6)C=N4)C=C2)CCOCC1 |
| Hazard Information | Back Directory | [Uses]
DMH 2 is a selective BMP inhibitor. | [Biological Activity]
DMH2 is a potent antagonist of the BMP receptor activin receptor-like kinase 3 (ALK3BMPR-IA) th at enhance liver regeneration. DMH2 potently inhibits BMP signaling and induced the greatest reduction of cell growth and expression of Id family members in H1299 non-small cell lung carcinoma cells. | [in vivo]
DMH2 (0-2 mg/kg, IP, twice daily, for 2 days prior to PH (partial hepatectomy) and for 2 days after PH) increases hepatocyte proliferation from 13.7% to 26.9% at 2 mg/kg[2]. | Animal Model: | C57BL/6 mice (7-8 weeks, male)[2] | | Dosage: | 0.5, 1, 2 mg/kg | | Administration: | IP, twice daily, for 2 days prior to PH and for 2 days after PH (partial hepatectomy) | | Result: | Increased hepatocyte proliferation from 13.7% to 26.9% at 2 mg/kg. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|